AgingResearch.NewsJoin free

Phase 1Completed

Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

A Two-Treatment, Sequential, Crossover Study of the Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (Infectious Rhinitis)

Sponsor
ARS Pharmaceuticals, Inc. (Industry)
Enrollment
15 enrolled
Conditions
Upper Respiratory Tract Infection
Interventions
ARS-1 with URTI; ARS-1 without URTI
Ages
adults
Registry
NCT04930900

Full record on ClinicalTrials.gov

From the registry

This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.

Primary outcomes

  • To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration
  • To evaluate the bioavailability (AUC0-t) of ARS-1 after intranasal administration
  • To evaluate the bioavailability (tmax) of ARS-1 after intranasal administration

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Started

  5. Registered